Erasca Tightens Timeline for ERAS-0015 Phase 1 Data

An announcement from Erasca ( (ERAS) ) is now available.

On April 21, 2026, Erasca, Inc. announced it had tightened the expected timing for a Phase 1 monotherapy data readout for its pan-RAS molecular glue candidate ERAS-0015 to no later than mid-May 2026, from a prior target of the first half of 2026. The drug is being tested by Erasca in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors and by licensor Guangzhou Joyo Pharmatech in the JYP0015M101 trial in China in patients with advanced solid tumors harboring specific RAS mutations, signaling an important near-term clinical milestone for its RAS-focused oncology pipeline.

The most recent analyst rating on (ERAS) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on Erasca stock, see the ERAS Stock Forecast page.

Spark’s Take on ERAS Stock

According to Spark, TipRanks’ AI Analyst, ERAS is a Neutral.

The score is held back primarily by weak financial performance (no revenue, large ongoing losses and cash burn), partially offset by strong technical momentum and positive corporate events that extend liquidity runway and highlight clinical progress. Valuation signals remain constrained due to ongoing losses and lack of dividend support.

To see Spark’s full report on ERAS stock, click here.

More about Erasca

Erasca, Inc. is a biotechnology company focused on developing targeted cancer therapies, with a particular emphasis on RAS-mutant and other genetically defined solid tumors. Its pipeline includes small-molecule and molecular glue candidates designed to inhibit oncogenic drivers and address unmet needs in advanced solid tumor indications worldwide.

Average Trading Volume: 5,312,335

Technical Sentiment Signal: Buy

Current Market Cap: $5.66B

For a thorough assessment of ERAS stock, go to TipRanks’ Stock Analysis page.